MASP2
Mannan-binding lectin serine protease 2
As of the edition of 20 October 2026, MASP2 (mannan-binding lectin serine protease 2, UniProt O00187) has 2 drugs tested at it and 2 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- O00187
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 10
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Blood and lymph; Immune system; Infections; Lungs and airways; Skin and connective tissue
- Registered trials of its drugs
- 10
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Narsoplimab | Marketed | Phase 3 | Ends 2037 |
| SHR-2010 | Stopped | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| Guangdong Hengrui Pharmaceutical | Route A |
| Omeros | Route B |
The other 0 companies at MASP2
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at MASP2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.